ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report)’s stock price gapped down before the market opened on Thursday. The stock had previously closed at $14.88, but opened at $13.60. ChronoScale Corporation Common Stock shares last traded at $13.20, with a volume of 61,246 shares.
Key Stories Impacting ChronoScale Corporation Common Stock
Here are the key news stories impacting ChronoScale Corporation Common Stock this week:
- Positive Sentiment: Compass Point initiated coverage with a Buy rating and a $25 price target, implying approximately 65% upside from the recently quoted $15.15 level. The new coverage may support the stock by adding a bullish view and highlighting potential valuation upside.
- Positive Sentiment: Northland Securities maintained an Outperform rating and a substantially higher $32 price target. Its forecasts anticipate a return to quarterly profitability of $0.16 EPS in Q4 2028, suggesting analysts expect longer-term improvement as ChronoScale scales its AI-focused accelerated-computing platform.
- Neutral Sentiment: ChronoScale reported fiscal first-quarter 2027 results for the period ended August 31, 2026. The results are the most important near-term catalyst, with investors likely focused on revenue growth, losses, cash resources and demand for the company’s AI infrastructure offerings. ChronoScale Reports Fiscal First Quarter 2027 Results
- Negative Sentiment: Despite the optimistic ratings, Northland projects continued losses: $0.39 per share for FY2027 and $0.15 per share for FY2028, with additional quarterly losses expected through Q3 2028. This indicates that the anticipated recovery remains several quarters away.
- Negative Sentiment: ChronoScale’s recent financial profile remains a concern, including negative earnings and margins, a current ratio of 0.51 and a negative return on equity. These factors can keep investors cautious while the company funds growth and works toward profitability. ChronoScale Fiscal Q1 Earnings Snapshot
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. Northland Securities began coverage on ChronoScale Corporation Common Stock in a research note on Friday, September 18th. They set an “outperform” rating and a $32.00 price objective on the stock. Compass Point initiated coverage on shares of ChronoScale Corporation Common Stock in a research note on Friday. They set a “buy” rating and a $25.00 target price on the stock. Finally, Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 9th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $21.00.
View Our Latest Research Report on ChronoScale Corporation Common Stock
ChronoScale Corporation Common Stock Price Performance
The company’s 50 day moving average is $19.78 and its 200 day moving average is $18.17. The company has a current ratio of 0.30, a quick ratio of 0.51 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -2.80 and a beta of 0.98.
ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report) last released its quarterly earnings data on Wednesday, October 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The company had revenue of $41.48 million during the quarter. Research analysts anticipate that ChronoScale Corporation Common Stock will post -0.39 EPS for the current fiscal year.
Institutional Investors Weigh In On ChronoScale Corporation Common Stock
An institutional investor recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc boosted its stake in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN – Free Report) by 104.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,338 shares of the company’s stock after acquiring an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned about 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the Securities and Exchange Commission. 6.42% of the stock is currently owned by institutional investors and hedge funds.
ChronoScale Corporation Common Stock Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.
Read More
- Five stocks we like better than ChronoScale Corporation Common Stock
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
- 3 Stocks Delivering Bigger Dividends Despite Market Uncertainty
Receive News & Ratings for ChronoScale Corporation Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChronoScale Corporation Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
